Duo Fu

Duo Fu

Auto-generated profile, based on publicly available information

Duo Fu

State Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian, 116024, PR China; School of Chemical Engineering, Dalian University of Technology, Dalian, 116024, PR China; School of Bioengineering, Dalian University of Technology, Dalian, 116024, PR China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2018 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
KMKun Ma
Kun Ma
DFDuo Fu
Duo Fu
YLYajun Liu
Yajun Liu
RDRui Dai
Rui Dai
DYDongli Yu
Dongli Yu
Chuanbin MaoChuanbin Mao
Chuanbin Mao
Nano-graphene oxide (NGO) has been proposed as a novel drug carrier. However, its poor biocompatibility and physiological stability as well as the lack of cancer targeting ability have limited its further application in cancer therapy. To solve this problem, we developed a novel nanohybrid, NGO/DOX@SPC-FA, by first allowing a soy phosphatidylcholine (SPC) membrane to encapsulate DOX-loaded NGO (NGO/DOX) and then modifying the SPC membrane with a PEGylated lipid–FA conjugate to achieve the presentation of cancer targeting folic acid (FA) on the nanohybrid surface. The SPC membrane (mimicking cell membrane) endowed the resultant nanohybrids (NGO/DOX@SPC-FA) with good stability and biocompatibility, high drug loading capability, efficient cellular uptake, and controlled drug release. Moreover, compared with NGO/DOX and SPC-modified NGO/DOX (NGO/DOX@SPC), the FA-modified NGO/DOX@SPC nanohybrids (NGO/DOX@SPC-FA) could deliver NGO/DOX to cancer cells with improved delivery and killing efficacy due to the presence of FA targeting motifs on their surface. The NGO/DOX@SPC-FA nanohybrids were found to be internalized specifically by FA-positive cancer cells (HeLa cells) through both macropinocytosis-directed engulfment and clathrin-dependent endocytosis, and then become localized into lysosomes. The in vivo biodistribution study showed that NGO/DOX@SPC-FA had high tumor targeting ability because of the active targeting mechanism with FA modification. The in vivo antitumor therapy study demonstrated that NGO/DOX@SPC-FA could significantly inhibit tumour growth and prolong the survival time of mice. Our results suggested that NGO/DOX@SPC-FA, as a novel drug delivery system with high drug loading and targeted delivery efficiency, holds promise for future cancer therapy.

1 March 2017 in Biomaterials
Verified
Journal Article
Closed access
KMKun Ma
Kun Ma
DFDuo Fu
Duo Fu
DYDongli Yu
Dongli Yu
CCChanghao Cui
Changhao Cui
LWLi Wang
Li Wang
Chuanbin MaoChuanbin Mao
Chuanbin Mao

14 August 2022 in Biomaterials
Verified
Journal Article
Closed access
DFDuo Fu
Duo Fu
MWMengjia Wang
Mengjia Wang
TYTao Yang
Tao Yang
MLMin Li
Min Li
ZLZhihui Liang
Zhihui Liang
Chuanbin MaoChuanbin Mao
Chuanbin Mao